Psychopharmacologic treatment of negative schizophrenic symptoms

Comprehensive Psychiatry

Volumn 35, Issue 1, 1994, Pages 16-28

  Opler, Lewis A ^a,b,c,d,e   Albert, David ^a,b,c,d,e   Ramirez, Paul M ^a,b,c,d,e  

^a Department of Psychiatry College of Physicians and Surgeons Columbia University ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d JACOBI MEDICAL CENTER   (United States)

^e LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; ANTIHISTAMINIC AGENT; CHOLECYSTOKININ; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LEVODOPA; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; PIMOZIDE; RISPERIDONE; SEROTONIN AGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; VASOPRESSIN; ZOTEPINE;

HUMAN; PATHOPHYSIOLOGY; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BRAIN; DRUG THERAPY, COMBINATION; HUMAN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0028115672     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-440X(94)90165-1     Document Type: Article

References (75)

1. Part III. Speculations on the Processes That Underlie Schizophrenic Symptoms and Signs
2. Molecular pathology of schizophrenia: more than one disease process?
3. Negative symptoms in schizophrenia
4. Negative vs. positive schizophrenia: definition and validation
5. Positive and negative syndromes in chronic schizophrenic inpatients
6. Positive and negative syndromes in schizophrenia: typological, dimensional, and pharmacological validation
7. The positive-negative dimension in schizophrenia: its validity and significance
8. Negative symptomatology in schizophrenia: a conceptual and empirical review
9. Cerebral dysfunction in schizophrenia and its relationship to positive and negative symptoms: a response to Suddath et al.
10. Neurocognitive features of chronic schizophrenic inpatients
11. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia
12. A discriminant validity study of negative symptoms with a special focus on depression and antipsychotic medication
13. Negative and deficit symptoms in schizophrenia do respond to neuroleptics
14. The positive-negative distinction in drug-free schizophrenic patients
15. Treatment of negative symptoms
16. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics
17. Deficit or negative syndrome?
18. Partial improvement in negative schizophrenic symptoms after amphetamine
19. Dextro-amphetamine diminishes negative symptoms in schizophrenia
20. Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology
21. Amantadine versus trihexiphenidyl in the treatment of neuroleptic-induced parkinsonism
22. The effect of amantadine on prolactin levels and galactorrhea on neuroleptic treated patients
23. Amantadine in the treatment of neuroendocrine side effects of neuroleptics
24. Neuroendocrine Side Effects of Neuroleptics
25. Dopamine agonists for negative symptoms in schizophrenia
26. Bromocriptine for “negative” schizophrenia
27. The effect of l-DOPA on young patients with simple schizophrenia, treated with neuroleptic drugs
28. l-Dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study
29. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia: theoretical implications for potency differences among neuroleptics
30. The neuroleptic hypothesis: study of the covariation of extrapyramidal and therapeutic drug effects
31. Treatment of negative schizophrenic symptoms with alprazolam: a preliminary open-label study
32. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms
33. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients
34. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates
35. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors
36. The use of antidepressants for negative symptoms in a subset of schizophrenic patients
37. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia
38. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients
39. The role of pimozide in clinical psychiatry: a review
40. Pimozide treatment of the negative schizophrenic syndrome: an open trial
41. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
42. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics
43. The Positive and Negative Syndrome Scale (PANSS): rationale and standardization
44. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists
45. A negative double-blind, placebo-controlled clinical trial of verapamil in chronic schizophrenia
46. Clinical and biochemical effects of verapamil administration to schizophrenic patients
47. Effects of verapamil administration on negative symptoms of chronic schizophrenia [letter]
48. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients
49. Antipsychotic effects of ceruletide (coerulein) on chronic schizophrenia [letter]
50. Cholecystokinin appears to have antipsychotic properties
51. Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory
52. Agranulocytosis during treatment with clozapine
53. Clozapine for treatment-resistant schizophrenia
54. Who should receive clozapine?
55. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years
56. Duration of a clozapine trial in neuroleptic-resistant schizophrenia [letter]
57. The Role of Serotonin in the Action of Atypical Antipsychotic Drugs
58. Clozapine in the treatment of negative symptoms in schizophrenia
59. Clozapine in the treatment of negative symptoms in schizophrenia
60. Clozapine in the treatment of negative syndrome in schizophrenia: a three-year follow-up study
61. 2 antagonistic properties
62. 2 antagonism in schizophrenia: clinical extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766)
63. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
64. Effect of famotidine on deficit symptoms of schizophrenia [letter]
65. 2-receptor antagonist, and negative symptoms of schizophrenia
66. Fenfluramine treatment of negative symptoms in older schizophrenic inpatients
67. L'amisulpride, neuroleptique et antidéficitaire
68. Zotepine in the treatment of negative symptoms in chronic schizophrenia
69. Clonidine treatment of schizophrenia: can we predict treatment response?
70. Testing systems for assessment of negative symptoms in schizophrenia
71. Dimensional perspective on schizophrenia
72. Hypofrontality in neurolepticnaive patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the tower of London
73. Negative symptoms and hypofrontality in chronic schizophrenia